Drug intelligence / Profile preview

iPD1 CD19 eCAR T cells

Development stage: Phase 1
Lead developer: Beijing Mali Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

iPD1 CD19 eCAR T cells represent a novel Chimeric Antigen Receptor (CAR) T-cell therapy engineered to target the CD19 antigen, a protein widely expressed on B-cell malignancies. The 'iPD1' component suggests an integrated strategy to counteract programmed cell death protein 1 (PD-1) mediated immune suppression, aiming to enhance the persistence and efficacy of the CAR T cells in the tumor microenvironment. This cellular immunotherapy is currently under investigation for the treatment of relapsed or refractory B-cell lymphoma.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on iPD1 CD19 eCAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPD1 CD19 eCAR T cells.

Explore the full profile